Discover the power of a burn up chart. See examples, learn how to create one, and track scope, progress, and team performance ...

Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to deploy and manage AI agents. Google Cloud has updated its Vertex AI Agent ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A former executive at Microsoft ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

There's more good news than bad news for this big biotech stock. Were Vertex's Q2 results horrible? Not at all. Instead, investors reacted negatively after the big biotech company announced two ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...